1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hepatitis - Pipeline Review, H2 2013

Hepatitis - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 42 pages

Hepatitis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Hepatitis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. Hepatitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatitis.
- A review of the Hepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hepatitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hepatitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hepatitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Hepatitis - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hepatitis Overview: 6
Therapeutics Development 7
An Overview of Pipeline Products for Hepatitis 7
Hepatitis Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Pre-Clinical Stage Products 11
Comparative Analysis 11
Hepatitis Therapeutics - Products under Development by Companies 12
Companies Involved in Hepatitis Therapeutics Development 13
EpiCept Corporation 13
MetrioPharm AG 14
GeneScience Pharmaceuticals Co., Ltd. 15
ChemoCentryx, Inc. 16
TVAX Biomedical, LLC 17
IRX Therapeutics, Inc. 18
Gaia BioPharma Limited 19
Hepatitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
GAI-122 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Methyl Inosine Monophosphate - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ALF-5755 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
MP-1031 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
TVI-Hepatitis-1 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
EP-1013 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
CXCR-6 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
thymalfasin - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Hepatitis Therapeutics - Drug Profile Updates 34
Hepatitis Therapeutics - Dormant Products 35
Hepatitis - Product Development Milestones 36
Featured News and Press Releases 36
Mar 04, 2013: Indian Patent Board Rules Against Bayer In Nexavar Lawsuit 36
Aug 22, 2012: FortuneRock Receives Chinese Approval To Begin Clinical Trials For Interferon-alpha2a 36
Apr 18, 2012: Vertex Pharma Announces Enrollment In Phase II Study Evaluating Combination Of INCIVEK, VX-222 And Ribavirin 36
Apr 18, 2012: Vertex Pharma And Alios BioPharma To Conduct Seven-Day Viral Kinetic Study Of ALS-2200 37
Apr 04, 2012: EpiCept's Pre-Clinical Research Concludes EP1013 As New Drug Candidate For Treatment Of Late-Stage Viral Hepatitis 37
Feb 22, 2011: Cytheris Announces Publication Of Preclinical Data Of Interleukin-7 In Cell 37
Nov 02, 2008: New Data Suggest Long-Term Treatment with BARACLUDE (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B 39
Aug 29, 2008: Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude (entecavir) as a Treatment Option for Chronic Hepatitis B. 39
Jun 24, 2008: NICE Issues Final Appraisal Determination (FAD) Which Recommends Baraclude (Entecavir) as a Treatment Option for Eligible Chronic Hepatitis B Patients. 40
Apr 26, 2008: BARACLUDE (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42



List of Tables

Number of Products Under Development for Hepatitis, H2 2013 7
Products under Development for Hepatitis - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
EpiCept Corporation, H2 2013 13
MetrioPharm AG, H2 2013 14
GeneScience Pharmaceuticals Co., Ltd., H2 2013 15
ChemoCentryx, Inc., H2 2013 16
TVAX Biomedical, LLC, H2 2013 17
IRX Therapeutics, Inc., H2 2013 18
Gaia BioPharma Limited, H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 24
Hepatitis Therapeutics - Drug Profile Updates 34
Hepatitis Therapeutics - Dormant Products 35



List of Figures

Number of Products under Development for Hepatitis, H2 2013 7
Products under Development for Hepatitis - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Pre-Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 20
Assessment by Route of Administration, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 22
Assessment by Molecule Type, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 24



Companies Mentioned

EpiCept Corporation
MetrioPharm AG
GeneScience Pharmaceuticals Co., Ltd.
ChemoCentryx, Inc.
TVAX Biomedical, LLC
IRX Therapeutics, Inc.
Gaia BioPharma Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19 Summary Cancer vaccines are being ...

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024

  • $ 4900
  • Industry report
  • November 2016
  • by Persistence Market Research

In this report, Persistence Market Research (PMR) offers an eight year forecast of the global hepatitis C treatment market between 2016 and 2024. The current study reveals the market trends and market ...

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2017

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2017

  • $ 2995
  • Industry report
  • February 2017
  • by Currentpartnering

Summary The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the co-development deals ...


Download Unlimited Documents from Trusted Public Sources

HIV AIDS Statistics and HIV Antiviral Market in China

  • February 2017
    11 pages
  • HIV AIDS  

    Infectious Dise...  

    HIV Antiviral  

  • China  

    United States  

View report >

Therapy Market

  • February 2017
    7 pages
  • Therapy  

View report >

Anesthetics and Therapy Market in the US

  • February 2017
    9 pages
  • Anesthetics  

    Therapy  

  • United States  

View report >

Related Market Segments :

Hepatitis

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.